Rectal CancerEndodrainNCT04735107
Mucosal Flap Reinforced Colorectal Anastomosis and Trans-Anal Vacuum Drainage: A Feasibility Study
A study testing colorectal anastomosis reinforcement and trans-anal drainage in people with Rectal Cancer, run by Comenius University at 1 site in Slovakia.
Trial summary
Background: Dehiscence of colorectal anastomosis is a serious complication associated with increased mortality and impaired functional and oncological outcomes. We hypothesised that anastomosis reinforcement and vacuum trans-anal drainage could eliminate some risk factors of colorectal anastomotic dehiscence,including… Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Rectal Cancer
- What is being tested?
- colorectal anastomosis reinforcement and trans-anal drainage
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteSlovakia
- Study dates
- 1 Nov 2018to 1 Sep 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with diagnosed extraperitoneal rectal cancer, cT1-cT4
- Patient with low anterior resection and double-stapled anastomosis technique
Who cannot join
- Patients not provided written informed consent
- Patients with cT4: with pelvic side wall involement, requiring pelvic more extensive procedure
- Patients with recurrent rectal cancer
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Low Anterior Resection Combined With Transanal Reinforcement and Endoluminal Sponge Vacuum Drainage
Background: Dehiscence of colorectal anastomosis is a serious complication associated with increased mortality and impaired functional and oncological outcomes. We hypothesised that anastomosis reinforcement and vacuum trans-anal drainage could eliminate some risk factors of colorectal anastomotic dehiscence,including mechanically stapled anastomosis instability and local infection.
Read the detailed description
The study included consecutive patients older than 18 years who had low anterior resection of the rectum and anastomosis performed by double-stapler technique, for rectal cancer located within 10 cm from the anal verge. All patients had undergone pelvic magnetic resonance imaging. Nutrition screening was performed in all patients. If patients had undergone neoadjuvant chemoradiotherapy (CHRT), restaging was performed within 6 weeks of CHRT completion, and surgery was performed 10 weeks after CHRT completion. For the surgical procedure, low anterior resection (LAR) was performed by experienced surgeons who perform more than 50 rectal procedures per year and have sufficient expertise in minimally invasive surgery. Oral bowel preparation was used preoperatively and antibiotics were administered according to protocol.
- Surgical technique The procedure milestones (descending colon blood perfusion, tension-free anastomosis, safely performed stapled anastomosis and reinforcement, and safely performed mucosal flap) were defined. Simultaneous checkpoints to control milestones were identified and methodology of their documentation (video, photography) were defined. The purpose was to achieve demonstrable control over the individual steps during the surgical procedure. 1.1 Abdominal phase Laparoscopic procedures were performed in the Lloyd-Davis position, using the 4-ports technique. During the abdominal phase, dissection was guided by a medio-lateral approach. A high tie of the a. mesenterica inferior (AMI) was performed in all patients. Dissection was performed medio-laterally and down to the pelvic floor according to the principles of total mesorectal excision (TME). The rectum was transected using an endostapler after lavage with Betadine solution (Egis Pharmaceuticals, PLS, Budapest, Hungary). Furthermore, the splenic flexure was fully mobilized using a combination of medio-lateral and lateral approaches. In most cases, the inferior mesenteric vein was divided. The marginal artery was dissected and the character of arterial blood flow was carefully evaluated; pulsatile arterial blood flow was considered as sign of adequate colon perfusion (Checkpoint 1). A specimen of tumor was pulled through the minilaparotomy and resected. The descending colon was divided at the level of the distal part and the colonic mucosa was again evaluated with respect to blood perfusion; a light red or pink colored mucosa and fresh light red capillary bleeding were considered as signs of good colonic mucosa perfusion (Checkpoint 2). The colon needed to lie freely in the sacrum excavation and no tension was allowed on the mesenterial site. This was confirmed by lifting the colon ventrally from the sacrum at the promontory level after anastomosis construction (Checkpoint 3). The anastomosis was performed end-to-end using a double-stapler technique, strictly between the descending colon and rectum in a tension-free manner. A pelvic drain was left in place till the third postoperative day. 1.2 Trans-anal phase As part of the trans-anal phase, a Lone Star retractor (Cooper Surgical, Inc. USA) and a plastic single use anoscope were applied. An initial, careful inspection and manual check of the stapler anastomosis integrity, the blood supply to the colonic mucosa, and signs of a tension-free anastomosis were performed (Checkpoint 4). The mucosal flap was subsequently created using individual polydiaxone (PDS) II 5/0 sutures (polydiaxonone, Ethicon, Johnson\&Johnson, USA): individual stitches were placed on each quadrant; and then another four stitches were applied in between. It is important to note that the condition of the mucosal flap upon creation were signs of a floppy, prolapsing colonic wall into the anastomosis. Finally, a sponge soaked (Endo-SPONGE, B. Braun, Germany) with povidone-iodine (Betadine, Egis Pharmaceuticals, Budapest, Hungary) was introduced into the anastomosis. The trans-anal sponge drain was removed 24 hrs postoperatively. 1.3 Fecal diversion The decision on diversion was based on intraoperative checkpoint adherence: when Checkpoint 6 and 7 were not fulfilled, an ileostomy was created.
- Follow up
The data regarding the type of procedure, type of anastomosis, stapler diameter, the number of stapler cartridges used, dissection of the mesenteric blood vessels, and complete histopathology were collected prospectively. C-reactive protein (CRP) levels were assessed on the third and fifth day after surgery.0 Patients were followed up for 3 months, and postoperative endoscopy was performed before discharge, usually on postoperative day 7, 1 month after surgery, and 3 months after surgery.
- Conditions
- Rectal Cancer
- Being tested
- colorectal anastomosis reinforcement and trans-anal drainage
- Keywords
- low anterior resection, anastomotic dehiscence
- Medical subject headings
- Rectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
colorectal anastomosis reinforcement and trans-anal drainageProcedure or surgery
Also called Mucosal flap double-stapled anastomosis reinforcement
Circular mucosal flap created to cover stapled anastomosis + vacuum sponge drainage
| Study group | Role | What they receive |
|---|---|---|
| Reinforcement | Experimental | Low anterior resection + mucosa flap reinforcement + vacuum sponge endoluminal drainage Receives: Procedure: colorectal anastomosis reinforcement and trans-anal drainage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of anastomotic leak
Leak of colorectal anastomosis proven by endoscopy/or/and computed tomography
Measured: 30 days
Defunction ileostomy rate
Rate of fecal diversion in group of treated patients
Measured: 30 days
Secondary outcomes (1)
Postoperative morbidity
Complications in postoperative period
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Feb 2021
- Study start1 Nov 2018
- Primary completion1 May 2021 (estimated)
- Study completion1 Sep 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Rectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Comenius University
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital, Martin
- Responsible party
- Principal investigator, Alexander Ferko, Comenius University
- Investigators
- Alexander Ferko, Prof.MD,PhD, Principal investigator, Comenius University, Jessenius Medical Faculty in Martin
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04735107
- Sponsor's protocol ID
- No 2018/16-UKMT-12
- Acronym
- Endodrain
- Status last verified
- Jan 2021
- First submitted
- 27 Jan 2021
- Last updated
- 2 Feb 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ferko A, Vana J, Adamik M, Svec A, Zacek M, Demeter M, Grendar M. Mucosa plication reinforced colorectal anastomosis and trans-anal vacuum drainage: a pilot study with preliminary results. Updates Surg. 2021 Dec;73(6):2145-2154. doi: 10.1007/s13304-021-01105-4. Epub 2021 Jun 5.
PubMed 34089500
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Low Anterior Resection Combined With Transanal Reinforcement and Endoluminal Sponge Vacuum Drainage
- ClinicalTrials.gov ID
- NCT04735107
- Acronym / sponsor ID
- Endodrain / No 2018/16-UKMT-12
- Conditions
- Rectal Cancer
- Keywords
- low anterior resection, anastomotic dehiscence
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Comenius UniversityUniversity, hospital or other
- Collaborators
- University Hospital, Martin
- Study start
- 1 Nov 2018 (actual)
- Primary completion
- 1 May 2021 (estimated)
- Study completion
- 1 Sep 2021 (estimated)
- First posted
- 2 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Dehiscence of colorectal anastomosis is a serious complication associated with increased mortality and impaired functional and oncological outcomes. We hypothesised that anastomosis reinforcement and vacuum trans-anal drainage could eliminate some risk factors of colorectal anastomotic dehiscence,including mechanically stapled anastomosis instability and local infection.
Detailed description
The study included consecutive patients older than 18 years who had low anterior resection of the rectum and anastomosis performed by double-stapler technique, for rectal cancer located within 10 cm from the anal verge. All patients had undergone pelvic magnetic resonance imaging. Nutrition screening was performed in all patients. If patients had undergone neoadjuvant chemoradiotherapy (CHRT), restaging was performed within 6 weeks of CHRT completion, and surgery was performed 10 weeks after CHRT completion. For the surgical procedure, low anterior resection (LAR) was performed by experienced surgeons who perform more than 50 rectal procedures per year and have sufficient expertise in minimally invasive surgery. Oral bowel preparation was used preoperatively and antibiotics were administered according to protocol.
- Surgical technique The procedure milestones (descending colon blood perfusion, tension-free anastomosis, safely performed stapled anastomosis and reinforcement, and safely performed mucosal flap) were defined. Simultaneous checkpoints to control milestones were identified and methodology of their documentation (video, photography) were defined. The purpose was to achieve demonstrable control over the individual steps during the surgical procedure. 1.1 Abdominal phase Laparoscopic procedures were performed in the Lloyd-Davis position, using the 4-ports technique. During the abdominal phase, dissection was guided by a medio-lateral approach. A high tie of the a. mesenterica inferior (AMI) was performed in all patients. Dissection was performed medio-laterally and down to the pelvic floor according to the principles of total mesorectal excision (TME). The rectum was transected using an endostapler after lavage with Betadine solution (Egis Pharmaceuticals, PLS, Budapest, Hungary). Furthermore, the splenic flexure was fully mobilized using a combination of medio-lateral and lateral approaches. In most cases, the inferior mesenteric vein was divided. The marginal artery was dissected and the character of arterial blood flow was carefully evaluated; pulsatile arterial blood flow was considered as sign of adequate colon perfusion (Checkpoint 1). A specimen of tumor was pulled through the minilaparotomy and resected. The descending colon was divided at the level of the distal part and the colonic mucosa was again evaluated with respect to blood perfusion; a light red or pink colored mucosa and fresh light red capillary bleeding were considered as signs of good colonic mucosa perfusion (Checkpoint 2). The colon needed to lie freely in the sacrum excavation and no tension was allowed on the mesenterial site. This was confirmed by lifting the colon ventrally from the sacrum at the promontory level after anastomosis construction (Checkpoint 3). The anastomosis was performed end-to-end using a double-stapler technique, strictly between the descending colon and rectum in a tension-free manner. A pelvic drain was left in place till the third postoperative day. 1.2 Trans-anal phase As part of the trans-anal phase, a Lone Star retractor (Cooper Surgical, Inc. USA) and a plastic single use anoscope were applied. An initial, careful inspection and manual check of the stapler anastomosis integrity, the blood supply to the colonic mucosa, and signs of a tension-free anastomosis were performed (Checkpoint 4). The mucosal flap was subsequently created using individual polydiaxone (PDS) II 5/0 sutures (polydiaxonone, Ethicon, Johnson\&Johnson, USA): individual stitches were placed on each quadrant; and then another four stitches were applied in between. It is important to note that the condition of the mucosal flap upon creation were signs of a floppy, prolapsing colonic wall into the anastomosis. Finally, a sponge soaked (Endo-SPONGE, B. Braun, Germany) with povidone-iodine (Betadine, Egis Pharmaceuticals, Budapest, Hungary) was introduced into the anastomosis. The trans-anal sponge drain was removed 24 hrs postoperatively. 1.3 Fecal diversion The decision on diversion was based on intraoperative checkpoint adherence: when Checkpoint 6 and 7 were not fulfilled, an ileostomy was created.
- Follow up
The data regarding the type of procedure, type of anastomosis, stapler diameter, the number of stapler cartridges used, dissection of the mesenteric blood vessels, and complete histopathology were collected prospectively. C-reactive protein (CRP) levels were assessed on the third and fifth day after surgery.0 Patients were followed up for 3 months, and postoperative endoscopy was performed before discharge, usually on postoperative day 7, 1 month after surgery, and 3 months after surgery.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Reinforcement | Experimental | Procedure: colorectal anastomosis reinforcement and trans-anal drainageLow anterior resection + mucosa flap reinforcement + vacuum sponge endoluminal drainage |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Patients with diagnosed extraperitoneal rectal cancer, cT1-cT4
- Patient with low anterior resection and double-stapled anastomosis technique
Key exclusion criteria (3 listed)
- Patients not provided written informed consent
- Patients with cT4: with pelvic side wall involement, requiring pelvic more extensive procedure
- Patients with recurrent rectal cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| colorectal anastomosis reinforcement and trans-anal drainageAlso: Mucosal flap double-stapled anastomosis reinforcementCircular mucosal flap created to cover stapled anastomosis + vacuum sponge drainage | Procedure or surgery | Reinforcement |
Primary outcome
Incidence of anastomotic leak
Time frame: 30 days
Leak of colorectal anastomosis proven by endoscopy/or/and computed tomography
Defunction ileostomy rate
Time frame: 30 days
Rate of fecal diversion in group of treated patients
1 secondary outcome
Postoperative morbidity
Time frame: 30 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2021.
- Derived from this study: PubMed 34089500Ferko A, Vana J, Adamik M, Svec A, Zacek M, Demeter M, Grendar M. Mucosa plication reinforced colorectal anastomosis and trans-anal vacuum drainage: a pilot study with preliminary results. Updates Surg. 2021 Dec;73(6):2145-2154. doi: 10.1007/s13304-021-01105-4. Epub 2021 Jun 5.
- Individual participant dataSharing planned: No
Related trials for Rectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexander Ferko, Prof.MD,PhD principal investigator
Comenius University, Jessenius Medical Faculty in Martin
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing colorectal anastomosis reinforcement and trans-anal drainage in people with Rectal Cancer, run by Comenius University at 1 site in Slovakia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Slovakia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of anastomotic leak (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04735107, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2021.